NEW YORK, July 11, 2017 /PRNewswire/ --
If you want a Stock Review on SGYP, NVO, PTX or DEPO then come over to http://dailystocktracker.com/register/and sign up for your free customized report today. For today, DailyStockTracker.com has issued research reports on four Drug Manufacturers stocks, particularly: Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Novo Nordisk A/S (NYSE: NVO), Pernix Therapeutics
New York headquartered Synergy Pharmaceuticals Inc.'s shares declined 0.45%, closing Monday's trading session at $4.44. The stock recorded a trading volume of 2.09 million shares. Shares of the Company have advanced 10.72% in the last month and 4.23% over the previous three months. The stock is trading 8.38% above its 50-day moving average. Additionally, shares of Synergy Pharma, which focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders, have a Relative Strength Index (RSI) of 53.59. See our free and comprehensive research report on SGYP at:
On Monday, shares in Bagsvaerd, Denmark headquartered Novo Nordisk A/S recorded a trading volume of 796,477 shares. The stock rose 0.26%, ending the day at $42.12. The Company's shares have advanced 18.98% in the previous three months and 17.46% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 0.35% and 12.23%, respectively. Furthermore, shares of Novo Nordisk, which engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide, have an RSI of 45.03.
On July 05th, 2017, Novo Nordisk announced that it is initiating a recall of insulin cartridge holders used in a small number of NovoPen Echo® batches, because they may crack or break if exposed to certain chemicals, like certain cleaning agents. Using a device with a cracked or broken cartridge holder may result in the device delivering a reduced dose of insulin, which could potentially lead to high, blood sugar. NVO free research report is just a click away at:
Morristown, New Jersey headquartered Pernix Therapeutics Holdings Inc.'s stock finished the day 2.60% higher at $3.95 with a total trading volume of 73,030 shares. Shares of the Company have advanced 5.90% in the previous three months and 103.61% on an YTD basis. The stock is trading above its 200-day moving average by 3.79%. Additionally, shares of Pernix Therapeutics, which focuses on the acquisition, development, and commercialization of prescription drugs primarily for the US market, have an RSI of 33.43.
On June 28th, 2017, Pernix Therapeutics announced that it has been added to the Russell Microcap® index following the annual reconstitution, which took effect after the US market closed on June 23rd, 2017. The Russell US Indexes are some of the leading US equity benchmarks for institutional investors. They are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Sign up for your complimentary report on PTX at:
Shares in Newark, California headquartered Depomed Inc. ended yesterday's session 1.84% lower at $10.66. The stock recorded a trading volume of 1.12 million shares. The Company's shares have advanced 1.62% in the last one month. The stock is trading 0.35% below its 50-day moving average. Moreover, shares of Depomed, which engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the US, have an RSI of 49.83. Register for free on DailyStockTracker.com and download the latest research report on DEPO at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Proton beam therapy is a type of external radiation treatment or radiotherapy that uses protons ...
Statins are a group of drugs which help to lower the blood cholesterol levels.
Niemann-Pick disease is a group of inherited metabolic disorders in which cholesterol and lipids ...View All